Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2017

01-12-2017 | Review Article

The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies

Authors: Maurizio Lucchesi, Iacopo Sardi, Gianfranco Puppo, Antonio Chella, Claudio Favre

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2017

Login to get access

Abstract

Modern immunotherapy with checkpoint inhibitors has changed clinical practice of adult patients with advanced cancer. Blockade of CTLA-4 and PD-1 pathways have shown survival benefits in different diseases. In children, combination of surgery, radiotherapy and chemotherapy have improved survival rates of solid tumors. However, the outcomes for subsets of patients such as those with high-grade, refractory, or metastatic disease remain extremely poor. Currently, the treatment of these patients is almost exclusively based on standard chemotherapy. The significant proportion of pediatric cancers with high number of mutations and subsequent high expression of neoantigens, together with the potential prognostic role of the immunosuppressive checkpoint molecules (CTLA-4, PD-L1) can represent a promising rationale that support the use of checkpoint inhibitors. We made a revision about emerging data regarding safety and activity of checkpoint inhibitors in children with solid tumors.
Literature
1.
Pandolfi F, Cianci R, Lolli S et al (2008) Strategies to overcome obstacles to successful immunotherapy of melanoma. Int J Immunopathol Pharmacol 21:493–500CrossRefPubMedPubMedCentral
2.
3.
Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 30:125–140CrossRefPubMed
4.
5.
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34CrossRefPubMed
6.
Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for check-point inhibitor-based immunotherapy. Lancet Oncol 17(12):542–551CrossRef
7.
Campbell BB, Angelini P, Fabrizio D et al (2017) Large scale tumor mutational burden analysis of pediatric tumors provides a diagnostic tool for germline predisposition and reveals novel candidates for immune checkpoint inhibition. Neuro-Oncology 19(S4):30CrossRef
8.
Hingorani P, Maas ML, Gustafson MP et al (2015) Increased CTLA-4(+) T cells and an increased ratio of monocytes with loss of class II (CD14(+) HLA-DR(lo/neg)) found in aggressive pediatric sarcoma patients. J Immunother Cancer 3:35CrossRefPubMedPubMedCentral
9.
Chowdhury F, Dunn S, Mitchell S et al (2015) PD-L1 and CD8+ PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. Oncoimmunology 4:e1029701CrossRef
10.
11.
Majzner RG, Simon JS, Grosso JF et al (2015) Assessment of PD-L1 expression and tumor-associated lymphocytes in pediatric cancer tissues. Cancer Res 75:249CrossRef
12.
Routh JC, Ashley RA, Sebo TJ et al (2008) B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J Urol 179:1954–1959CrossRefPubMedPubMedCentral
13.
14.
Merchant MS, Wright M, Baird K et al (2016) Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res 22:1364–1370CrossRefPubMed
15.
Bajčiová V (2015) Therapeutic effect and tolerance of ipilimumab in metastatic malignant melanoma in children—a case report. Klin Onkol 28(Suppl 4):115–120
16.
Shad AT, Huo JS, Darcy C et al (2017) Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr Blood Cancer 64(3):e26257CrossRef
17.
Foran AE, Nadel HR, Lee AF, Savage KJ, Deyell RJ (2016) Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J Pediatr Hematol Oncol 39(5):e263–e266CrossRef
18.
Bouffet E, Larouche V, Campbell BB et al (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211CrossRefPubMed
19.
Blumenthal DT, Yalon M, Vainer GW et al (2016) Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol 129:453–460CrossRefPubMed
20.
Barrett D, Fish JD, Grupp S (2010) Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin N Am 57:47–66CrossRef
21.
Saha A, Aoyama K, Taylor PA et al (2013) Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood 122:3062–3073CrossRefPubMedPubMedCentral
22.
Blazar BR, Carreno BM, Panoskaltsis-Mortari A et al (2003) Blockade of programmed death-1 engagement accelerates graft-versus-host dis- ease lethality by an IFN-gamma-dependent mechanism. J Immunol 171:1272–1277CrossRefPubMed
23.
24.
25.
Shlien A, Campbell BB, de Borja R et al (2015) Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet 47:257–262CrossRefPubMed
26.
Durno CA, Aronson M, Tabori U et al (2012) Oncologic surveillance for subjects with biallelic mismatch repair gene mutations: 10 year follow-up of a kindred. Pediatr Blood Cancer 59:652–656CrossRefPubMed
27.
Zhu X, McDowell MM, Newman WC et al (2017) Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr 19:249–253CrossRefPubMed
28.
Prins RM, Soto H, Konkankit V et al (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615CrossRefPubMed
29.
Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534-542CrossRef
30.
Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697CrossRefPubMed
31.
Metadata
Title
The dawn of “immune-revolution” in children: early experiences with checkpoint inhibitors in childhood malignancies
Authors
Maurizio Lucchesi
Iacopo Sardi
Gianfranco Puppo
Antonio Chella
Claudio Favre
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2017
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-017-3450-2

Other articles of this Issue 6/2017

Cancer Chemotherapy and Pharmacology 6/2017 Go to the issue

Original Article

Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

Review Article

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea

Original Article

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Original Article

Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers

Original Article

Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)

Original Article

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits